"Amoxicillin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A broad-spectrum semisynthetic antibiotic similar to AMPICILLIN except that its resistance to gastric acid permits higher serum levels with oral administration.
| Descriptor ID |
D000658
|
| MeSH Number(s) |
D02.065.589.099.750.750.050.050 D02.886.108.750.750.050.050 D03.633.100.300.750.750.050.050
|
| Concept/Terms |
Amoxicillin- Amoxicillin
- Amoxycillin
- Amoxicillin Trihydrate
- Trihydrate, Amoxicillin
- Hydroxyampicillin
Clamoxyl- Clamoxyl
- Penamox
- Clamoxyl G.A.
- G.A., Clamoxyl
- Clamoxyl Parenteral
- Parenteral, Clamoxyl
|
Below are MeSH descriptors whose meaning is more general than "Amoxicillin".
Below are MeSH descriptors whose meaning is more specific than "Amoxicillin".
This graph shows the total number of publications written about "Amoxicillin" by people in this website by year, and whether "Amoxicillin" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 1 | 0 | 1 |
| 1995 | 3 | 0 | 3 |
| 1996 | 3 | 2 | 5 |
| 1997 | 3 | 0 | 3 |
| 1998 | 1 | 2 | 3 |
| 1999 | 4 | 1 | 5 |
| 2000 | 0 | 1 | 1 |
| 2001 | 1 | 0 | 1 |
| 2002 | 0 | 1 | 1 |
| 2003 | 0 | 2 | 2 |
| 2005 | 1 | 1 | 2 |
| 2006 | 2 | 3 | 5 |
| 2008 | 0 | 2 | 2 |
| 2009 | 0 | 2 | 2 |
| 2010 | 2 | 1 | 3 |
| 2011 | 2 | 2 | 4 |
| 2012 | 2 | 0 | 2 |
| 2013 | 2 | 2 | 4 |
| 2014 | 1 | 1 | 2 |
| 2015 | 2 | 0 | 2 |
| 2016 | 2 | 4 | 6 |
| 2017 | 2 | 3 | 5 |
| 2018 | 0 | 5 | 5 |
| 2019 | 1 | 1 | 2 |
| 2020 | 5 | 3 | 8 |
| 2021 | 0 | 3 | 3 |
| 2022 | 0 | 3 | 3 |
| 2023 | 1 | 7 | 8 |
| 2024 | 2 | 1 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Amoxicillin" by people in Profiles.
-
Synergistic effects of novel penicillin-binding protein 1A amino acid substitutions contribute to high-level amoxicillin resistance of Helicobacter pylori. mSphere. 2024 Aug 28; 9(8):e0008924.
-
Cut-off value of clarithromycin resistance in the treatment of Helicobacter pylori infection: how low is low? Gut. 2024 01 05; 73(2):374-375.
-
A pilot study evaluating high dose esomeprazole, bismuth subcitrate and amoxicillin for eradicating Helicobacter pylori infection in Iran. Helicobacter. 2024 Jan-Feb; 29(1):e13061.
-
Management of Helicobacter pylori treatment failures: A large population-based study (HP treatment failures trial). PLoS One. 2023; 18(11):e0294403.
-
Primary antibiotic resistance of Helicobacter pylori in the Asia-Pacific region between 1990 and 2022: an updated systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2024 Jan; 9(1):56-67.
-
Pilot studies of vonoprazan-containing Helicobacter pylori eradication therapy suggest Thailand may be more similar to the US than Japan. Helicobacter. 2023 Dec; 28(6):e13019.
-
Hybrid, High-Dose Dual and Bismuth Quadruple Therapies for First-Line Treatment of Helicobacter pylori Infection in Taiwan: A Multicenter, Open-Label, Randomized Trial. Am J Gastroenterol. 2023 07 01; 118(7):1184-1195.
-
Why the Vonoprazan Helicobacter pylori Therapies in the US-European Trial Produced Unacceptable Cure Rates. Dig Dis Sci. 2023 05; 68(5):1691-1697.
-
Response to: a true point-of-care molecular testing method for tailored therapy for Helicobacter pylori eradication. Expert Rev Gastroenterol Hepatol. 2023 03; 17(3):311.
-
Fourteen-day vonoprazan and low- or high-dose amoxicillin dual therapy for eradicating Helicobacter pylori infection: A prospective, open-labeled, randomized non-inferiority clinical study. Front Immunol. 2022; 13:1049908.